Company / Depreciation & Amortization
MoonLake Immunotherapeutics Depreciation & Amortization History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$2.6M
FY2025
5-year range
$5.0K / $2.6M
FY2021-FY2025
Trend
+88.9%
vs FY2024
Sector context
#92 of 168
Health Care
What the data says
At $3M, MoonLake Immunotherapeutics's depreciation & amortization ranks #77 of 168 in the Health Care sector. Depreciation & Amortization has increased for 4 consecutive years, from $4,971 in FY2021 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 3-year CAGR of +151.3%.
Increased from $370,000 to $3M over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +151.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#77 of 168 in Health CareTop 45% of 168This company $2.6M Sector average $212.9M
▼
-98.8% below sector average
Key checks
Key Insights
- MoonLake Immunotherapeutics's depreciation & amortization has grown for 4 consecutive years.
- 3-year CAGR of +151.3%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 88.9% year-over-year.
- Ranks #92 out of 168 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.6M | +88.9% |
| FY2024 | $1.4M | +274.3% |
| FY2023 | $370.0K | +124.5% |
| FY2022 | $164.8K | +3214.9% |
| FY2021 | $5.0K | - |
| FY2020 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026